* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIPO vs IOBTQ, WINT, CYTOF: Buyback Yield % Comparison
For the Biotechnology subindustry, Lipella Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipella Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Lipella Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipella Pharmaceuticals (LIPO) has a Buyback Yield % of -830.77 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lipella Pharmaceuticals and its competitors. According to the industry distribution chart, Lipella Pharmaceuticals ranks #741 out of 745 companies in the Biotechnology industry, placing it in the top 99.5%.
Is Lipella Pharmaceuticals' Buyback Yield % too high?
Lipella Pharmaceuticals' current Buyback Yield % is -830.77. Based on the distribution chart, Lipella Pharmaceuticals ranks #741 out of 745 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lipella Pharmaceuticals has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lipella Pharmaceuticals' Buyback Yield % compare to IOBTQ and WINT?
According to the Biotechnology industry distribution chart, Lipella Pharmaceuticals ranks #741 out of 745 companies for Buyback Yield %. This places Lipella Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lipella Pharmaceuticals and its competitors. Lipella Pharmaceuticals's current Buyback Yield % is -830.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.68, compared to a current price of $0.13 — trading 98.5% below its estimated fair value. The current Buyback Yield % is -830.77. Lipella Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current Buyback Yield % is -830.77 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lipella Pharmaceuticals (LIPO) Overvalued in 2026?
Based on GuruFocus' analysis, Lipella Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.13 is trading 98.5% below its estimated GF Value™ of $8.68.
GuruFocus considers Lipella Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LIPO:
Buyback Yield %: -830.77
GF Value™: $8.68 vs. price of $0.13 (98.5% below fair value)
No single metric tells the full story. See the LIPO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
35GF Score
Get the complete analysis for LIPO
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIPO has been successfully added to your 
